Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PCAR 19B

Next Previous
Drug Profile

PCAR 19B

Alternative Names: Anti-CD19-Car T cell therapy; PCAR-19B

Latest Information Update: 04 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Precision Biotech Co., Ltd
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase I/II B-cell lymphoma; Lymphoid leukaemia
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Dec 2024 Efficacy and adverse events data from a phase II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Refractory metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
  • 13 Jun 2024 Efficacy and adverse event data from a phase I/II trial in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma presented at the 29th Congress of the European Haematology Association (EHA-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top